echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Luye Pharma's "Lismin Transdermal Patch" for the treatment of mild to moderate AD will be approved soon in China

    Luye Pharma's "Lismin Transdermal Patch" for the treatment of mild to moderate AD will be approved soon in China

    • Last Update: 2020-05-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Photo Source: Insight Database (https://db.dxy.cn/v5)'s patch was developed by the transderbis ant development platform of Luye Pharma AG, a German subsidiary of the LeafY Bloc, and its preparation process is protected by multiple patents worldwideThe product through the skin is absorbed by the human body, avoiding the past oral medicine caused by gastrointestinal discomfort and some patients difficult to swallow the problemCompared with traditional tablets, it can effectively reduce the frequency of administration, reduce the fluctuation of blood concentration, and provide a smooth and sustained release of drugsCurrently, Greenleaf Pharmaceuticals' Lites has been marketed in more than 20 countries around the world and is performing wellPublic data show that in 2018 the U.Sand European markets of Liss's ming transdermal paste product category sales reached $452 millionthe World Alzheimer's Report 2018 shows that 50 million people worldwide will be living with dementia in 2018, a figure that is expected to reach 82 million by 2030; There are very few new drugs approved by the FDA in this field, and Lissis is currently a first-line drug for Alzheimer's diseaseCurrently, China has the highest number of People with Alzheimer's disease, with an estimated 28 million by 2050By 2017, AD was becoming the 5th leading cause of death in ChineseTherefore, the domestic AD market has great potential, Liss's ming paste in China has a good market potentialInsight database shows that only Novartis's Aisner, which is currently listed in China, was approved for import in February 2019, and because Bebe trials are being carried out by Jiangsu Wanbang and Beijing Ted PharmaceuticalsImage Source: Insight Database (https://db.dxy.cn/v5)original title: Green Leaf Pharmaceuticals's "Liss's Clear Transcutie Sticker" is about to be approved in the country to treat mild moderate Alzheimer's disease
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.